A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 245 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 Why investing in cancer research is good for the economy July 1, 2022 An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 ¿Puede protegerlo un “bronceado base” de las quemaduras solares y del... August 31, 2023 Load more HOT NEWS Grandma Saves Her Money To Put Up A Billboard For Everyone... An Oncology Hospital at Home Model of Acute Care Shows Promise Man Walks Entire Continent To Spread Awareness About Mental Health &... Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With...
